Pandemic 2009 H1N1 vaccine protects against 1918 Spanish influenza virus

Rafael A. Medina, Balaji Manicassamy, Silke Stertz, Christopher W. Seibert, Rong Hai, Robert B. Belshe, Sharon E. Frey, Christopher F. Basler, Peter Palese and Adolfo García-Sastre ()
Additional contact information
Rafael A. Medina: Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029, USA.
Balaji Manicassamy: Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029, USA.
Silke Stertz: Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029, USA.
Christopher W. Seibert: Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029, USA.
Rong Hai: Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029, USA.
Robert B. Belshe: NIAID Vaccine and Treatment Evaluation Unit, Saint Louis University, 1100 S Grand Blvd, St. Louis, MO 63104, USA.
Sharon E. Frey: NIAID Vaccine and Treatment Evaluation Unit, Saint Louis University, 1100 S Grand Blvd, St. Louis, MO 63104, USA.
Christopher F. Basler: Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029, USA.
Peter Palese: Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029, USA.
Adolfo García-Sastre: Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029, USA.

Nature Communications, 2010, vol. 1, issue 1, 1-6

Abstract: Abstract The 1918 influenza A virus caused the most devastating pandemic, killing approximately 50 million people worldwide. Immunization with 1918-like and classical swine H1N1 virus vaccines results in cross-protective antibodies against the 2009 H1N1 pandemic influenza, indicating antigenic similarities among these viruses. In this study, we demonstrate that vaccination with the 2009 pandemic H1N1 vaccine elicits 1918 virus cross-protective antibodies in mice and humans, and that vaccination or passive transfer of human-positive sera reduced morbidity and conferred full protection from lethal challenge with the 1918 virus in mice. The spread of the 2009 H1N1 influenza virus in the population worldwide, in addition to the large number of individuals already vaccinated, suggests that a large proportion of the population now have cross-protective antibodies against the 1918 virus, greatly alleviating concerns and fears regarding the accidental exposure/release of the 1918 virus from the laboratory and the use of the virus as a bioterrorist agent.

Date: 2010
References: Add references at CitEc
Citations: View citations in EconPapers (3)

Downloads: (external link)
https://www.nature.com/articles/ncomms1026 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:1:y:2010:i:1:d:10.1038_ncomms1026

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/ncomms1026

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().